ReposiTrak Q4 Earnings Call Highlights

Key Points

• Fiscal 2026 performance improved: Revenue rose 3% to $23.3 million, while lower operating expenses expanded the operating margin to 33.7%. Operating income increased 26% and diluted EPS climbed 13% to $0.39.
• Growth initiatives are focused on traceability and merchandising: ReposiTrak expects interest in FDA food-traceability solutions to increase ahead of the July 2028 compliance deadline. Its new Touchless Merchandising offering has already secured several contracts and is expected to become a meaningful contributor from fiscal 2027 onward.
• Strong balance sheet supports shareholder returns: The company ended the year with $27.3 million in cash, no bank debt, and $8.3 million in operating cash flow. It repurchased shares, paid quarterly dividends, and plans to redeem its remaining preferred shares by December 2026, subject to conditions.

ReposiTrak NYSE: TRAK reported fiscal 2026 revenue growth, wider operating margins and higher earnings as the company continued shifting its business mix toward recurring software-as-a-service revenue while reducing operating expenses.

For the fiscal year ended June 30, 2026, revenue rose 3% to $23.3 million from $22.6 million, while recurring revenue increased 4%, Chief Financial Officer John Merrill said during the company’s fourth-quarter earnings call. Operating expenses declined 6% to $15.4 million, contributing to an operating-margin expansion to about 33.7%, from 27.5% a year earlier.

Income from operations increased 26% to $7.8 million, and GAAP net income rose 8% to $7.6 million. Net income available to common shareholders increased 12% to $7.4 million. Diluted earnings per share climbed 13% to $0.39, compared with $0.35 in fiscal 2025.

Merrill said the company deliberately deemphasized some high-touch, low-margin revenue streams in favor of opportunities with greater profitability and growth potential. That decision moderated top-line growth but improved the company’s operating-margin profile, he said.

Fourth-Quarter Results and Tax Impact

Fourth-quarter revenue declined 3% year over year to $5.6 million. Merrill attributed the comparison in part to an accelerated pace of traceability activity in the second half of the prior year, when the food industry was preparing for the Food and Drug Administration’s original January 2026 compliance deadline for food traceability requirements.

The FDA has since extended the compliance date to July 20, 2028, and Congress has directed the agency not to enforce the food traceability rule before that date, Merrill said. He added that ReposiTrak expects customer activity could increase as the industry prepares for the new deadline.

Despite the quarterly revenue decline, fourth-quarter operating expenses fell 11% to $3.7 million. Income from operations rose 19% to $1.9 million, while GAAP net income increased 16% to $2.1 million. Quarterly diluted earnings per share were $0.11, up about 20% from the prior-year quarter.

The company’s income tax provision increased to about $2 million in fiscal 2026 from roughly $700,000 a year earlier as it nears the end of the benefit period related to historical federal and state net operating losses. Merrill said the increase in tax expense was about $1.3 million, or approximately $0.065 per share, compared with the prior year. ReposiTrak’s effective tax rate in fiscal 2026 was approximately 21% federally and 3% at the state level.

Touchless Merchandising Initiative

Chairman and Chief Executive Officer Randy Fields highlighted the company’s new Touchless Merchandising offering, which combines ReposiTrak’s supply-chain data and analytics with merchandising capabilities from SPAR Group. Fields said the service is intended to address out-of-stocks and shelf-stocking problems in the direct-store-delivery segment of grocery retail.

According to Fields, direct-store delivery accounts for more than 30% of grocery sales. In that model, suppliers deliver products directly to retail stores and are expected to stock and maintain their products on shelves. Fields said suppliers have reduced the frequency of merchandising visits as costs have risen, contributing to out-of-stocks and lower sales.

“Visibility without action does not solve the root problems,” Fields said, describing the company’s aim to pair data identifying supply-chain issues with personnel able to address them in stores.

ReposiTrak introduced the offering about a month before the call and had already signed and begun executing several contracts, Fields said. He expects the initiative to generate some revenue in the current quarter and become a “significant and meaningful” contributor in fiscal 2027 and beyond. He also cited cross-selling opportunities between ReposiTrak and SPAR customers.

The company is integrating its technology and reporting systems with SPAR so the businesses can share a common view of customers, Fields said. ReposiTrak is also refreshing much of its technology stack, including deeper artificial-intelligence capabilities, new-product investments and expanded supply-chain analytics.

Traceability Outlook

Fields said discussions with FDA staff reinforced his view that the agency does not intend to further postpone implementation of FSMA Rule 204. He expects inbound inquiries and interest in traceability to increase by year-end, with a meaningful business impact in 2027 as the 2028 compliance date approaches.

Fields pointed to recent food-safety incidents as evidence of the need for end-to-end traceability, saying faster identification of affected products and their sources can reduce both human and economic costs. He said ReposiTrak expects traceability revenue to grow more rapidly as the deadline nears.

Cash, Repurchases and Dividends

ReposiTrak ended fiscal 2026 with $27.3 million in cash and a $3 million note receivable from SPAR Group. Cash from operations totaled about $8.3 million, compared with $8.4 million in the prior year, and the company reported no bank debt.

• Repurchased and canceled about 144,000 common shares during fiscal 2026 for approximately $1.8 million, at an average price of $12.50 per share.
• Redeemed 175,000 preferred shares for approximately $1.9 million during the year.
• Had approximately $6 million remaining under its $21 million common-share repurchase authorization as of June 30.
• Declared quarterly dividends of $0.02 per share in June and September.

Merrill said the company’s capital-allocation objective remains returning approximately 50% of annual operating cash flow to shareholders while retaining the remainder to support the balance sheet and future operations. ReposiTrak aims to redeem its remaining preferred shares by December 2026, subject to business conditions, liquidity needs and board review.

About ReposiTrak (NYSE:TRAK)

ReposiTrak, Inc develops and operates a cloud-based supply chain management platform designed to improve product traceability, compliance and information exchange. Its technology connects retailers, wholesalers, distributors, manufacturers and suppliers, helping trading partners share standardized product, supplier and transaction data across complex supply chains.

The company's offerings include the ReposiTrak Traceability Network and related compliance and supply chain applications. These tools support supplier onboarding, product and facility information management, food safety documentation, regulatory compliance, recall readiness and electronic tracking of products through the supply chain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.